January 21, 2016
Wellesley, Mass., January 21, 2016 – Liquid biopsy has demonstrated its clinical utility in several key applications that have spurred booming growth in the market for liquid biopsy diagnostics. BCC Research reveals in its new report that this industry is poised to break into multiple applications, including the average-risk NIPT, cancer monitoring and organ transplantation surveillance segments.
The global liquid biopsy market, which totaled $1.6 billion in 2015, is growing at a five-year compound annual growth rate (CAGR) of 22.3% that should bring its value to nearly $4.5 billion by 2020. The two main applications for liquid biopsy are cancer and non-cancer (reproductive health and organ transplant diagnostics). The cancer market, the fastest growing segment with a five-year CAGR of 36.2%, reached $414.5 million in 2015 and should reach $1.9 billion by 2020. The global non-cancer market, the larger segment, totaled $1.2 billion in 2015. Growing at a five-year CAGR of 15.7%, it should reach $2.5 billion by 2020.
The liquid biopsy workflow is continuously improving, which is helping drive its adoption in clinical applications. On the workflow upstream side, technologies for cell capture, sample preparation and DNA amplification are making significant progress. On the workflow downstream side, new techniques like droplet digital PCR are emerging, and established techniques such as NGS and qPCR are incrementally improving.
Growing support by the medical communities is helping to drive growth for the liquid biopsy market. For noninvasive prenatal testing (NIPT), the key medical societies have endorsed its application for high-risk pregnant women. For other markets in cancer or transplantation medicine, a growing body of clinical evidence is critical to garner the support of key stakeholders for liquid biopsy diagnostics.
Early detection is an emerging application for liquid biopsy. For early cancer detection, it is important to use genetic biomarkers that can identify the very earliest premalignant genetic changes that occur at or before the onset of malignant cancer. Much fundamental scientific research continues to discover these genetic biomarkers.
“A main objective of post-transplant surveillance is to improve the outcomes for patients,” says BCC Research analyst John Bergin. “A key driving force for the use of liquid biopsy is clinical evidence that it does. During the past several years, this evidence has become stronger as a result of multiple studies using cfDNA as a biomarker. It is expected that this evidence, together with ongoing efforts by companies developing these biomarkers, will contribute to the market growth of this application in the future.”
Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets (BIO150A) examines biopsy technologies, clinical applications, industry structure, key liquid biopsy funding initiatives, global markets, patent statuses, and companies. Analyses of global market drivers and trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020 also are provided.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at firstname.lastname@example.org.
Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets( BIO150A )
Publish Date: Jan 2016
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email email@example.com or visit www.bccresearch.com/media to request access to our library of market research.